October 9, 2024

You are invited to join our President and CEO, Paul J. Diaz, and other members of the Myriad Leadership team, for the upcoming Myriad Genetics Investor Event. We will share our long-term growth strategy operational initiatives, and scientific and clinical advancements reflected in our product pipeline, as well as long-term financial goals.

Register to attend the event online

Events & Presentations

  • Investor Day 2024

    10/09/2024 | 6:00am PDT / 9:00am EDT

    Watch the webcast

  • Morgan Stanley 22nd Annual Global Healthcare Conference

    09/05/2024 | 4:00am PDT / 7:00am EDT

    Watch the webcast

  • Wells Fargo Healthcare Conference 2024

    09/04/2024 | 10:30am PDT / 1:30pm EDT

    Watch the webcast
View all events

Financial Reports and Filings

Date Filing Title Downloads
09/23/2024 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
09/23/2024 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
09/23/2024 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
09/16/2024 144 Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing RTF XLS PDF HTML XBRL
09/12/2024 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
09/12/2024 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
09/11/2024 144 Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing RTF XLS PDF HTML XBRL
09/11/2024 144 Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing RTF XLS PDF HTML XBRL
09/09/2024 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
09/09/2024 144 Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing RTF XLS PDF HTML XBRL
View all filings

Latest News

Myriad Genetics and Ultima Genomics to Explore the UG 100™ Sequencing Platform to Advance Clinical Test Offerings in Oncology and Reproductive Genomics Thumbnail

Myriad Genetics and Ultima Genomics to Explore the UG 100™ Sequencing Platform to Advance Clinical Test Offerings in Oncology and Reproductive Genomics

Oct 03, 2024 | Products

Read more
Myriad Genetics Announces Third Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date Thumbnail

Myriad Genetics Announces Third Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date

Oct 01, 2024 | Products | Corporate

Read more
Myriad Genetics to Share New Data Highlighting Genetic Testing Advancements at 2024 National Society of Genetic Counselors Annual Conference Thumbnail

Myriad Genetics to Share New Data Highlighting Genetic Testing Advancements at 2024 National Society of Genetic Counselors Annual Conference

Sep 18, 2024 | Products

Read more
View all news releases

Our commitment to social responsibility

At Myriad, social responsibility plays an important role in our approach to discovering and delivering valuable, transformative diagnostic tests across all major diseases to improve patients’ lives.

Learn more about the actions we’re taking in ESG

Read our ESG report
“As a leader in genetic testing and precision medicine, we understand the important role we play in advancing health equity and social justice. We also recognize our responsibility to operate in harmony with the environment which includes efforts to minimize our impact on the climate. These topics are directly linked with our purpose and values. We are proud to release our second annual environmental, social, and governance (ESG) report."

— Paul Diaz
President and CEO of Myriad Genetics

Our commitment to social responsibility

At Myriad, social responsibility plays an important role in our approach to discovering and delivering valuable, transformative diagnostic tests across all major diseases to improve patients’ lives.

Learn more about the actions we’re taking in ESG

Read our ESG report
“As a leader in genetic testing and precision medicine, we understand the important role we play in advancing health equity and social justice. We also recognize our responsibility to operate in harmony with the environment which includes efforts to minimize our impact on the climate. These topics are directly linked with our purpose and values. We are proud to release our second annual environmental, social, and governance (ESG) report."

— Paul Diaz
President and CEO of Myriad Genetics